Navigation Links
UCSF collaborates with Zcube to develop new ways to deliver drugs
Date:2/28/2011

A pill filled with microscopic, drug-laden adhesive patches is at the center of an agreement between UCSF and Zcube srl, the research corporate venture arm of Italian pharmaceutical leader Zambon Co., SpA, to license UCSF-developed microtechnology and support early research into new ways to deliver oral medications directly to a targeted site in the body.

This is the first sponsored research agreement between Zcube and UCSF, but is expected to be one of several such agreements with the biomedical university.

Sponsored research agreements underscore UCSF's commitment to finding innovative ways to bridge the gap between basic research and real-world applications. They reflect continued efforts by the UCSF Office of Technology Management and Industry Contracts Division to help faculty research efforts bear fruit, while protecting the academic freedom and basic research for which UCSF is widely known.

The initial two-year agreement will support research in the UCSF Desai Laboratory into delivering drugs directly to the small intestine and colon. The exclusive, worldwide license agreement will offer milestone payments and royalties for a UCSF-patented microdevice developed by the Desai Laboratory to deliver medications for various diseases, including colitis and irritable bowel syndrome.

"This partnership is unusual because it goes beyond licensing a technology, to fund early-stage innovation in drug delivery systems," said Tejal Desai, PhD, a professor of Bioengineering and Therapeutic Sciences in the UCSF School of Pharmacy. "That research is exactly what we need to do to see whether these systems will work."

The microdevice resembles a tiny, square Band-Aid with reservoirs in the middle for medication. Hundreds of these structures, each as wide as a human hair, would be packaged into a normal-sized pill, which would break down and release them into the intestine. The micropads would then stick onto the gastro-intestinal tract and deliver medications directly into the intestinal lining, then dissolve.

As a result, Desai said, the device has the potential of targeting the colon directly and increasing drug safety by reducing the amount of medication required in each dose. When properly targeted to other intestinal areas, the device also can significantly increase the amount of medication that reaches a patient's bloodstream.

Innovative technology that markedly improves both existing medication and new therapeutic agents is a key focus for Zcube, according to Zcube General Manager Lorenzo Pradella, PhD.

"The technology Zcube licensed from UCSF is a fantastic innovation for the oral delivery of single and multiple therapies into the gastro-intestinal tract, being extremely beneficial to many patients for different diseases," Pradella said. "It confirms Zcube's efforts to support emerging life science technologies that can improve health into the future."

Zcube was founded in 2003 to support emerging life science technology and research worldwide, Pradella said. Since 2007, Zcube has placed particular emphasis on drug delivery systems and medical devices in different therapeutic fields. Zcube has established collaborations to that end with universities in Europe, the United States and Israel, as well as with Mission Bay Capital and the California Institute for Quantitative Biosciences (QB3), which is headquartered on the UCSF Mission Bay campus.


'/>"/>

Contact: Kristen Bole
kristen.bole@ucsf.edu
415-502-6397
University of California - San Francisco
Source:Eurekalert

Related medicine news :

1. PeopleStreme Collaborates with SkillSoft for Learning Management Content
2. Eisner USA, LLC Collaborates with Surgical Review Corp to Provide Innovative Bariatric Devices to Bariatric Surgery Center of Excellence (BSCOE) Participants
3. Philips Collaborates with Microsoft to Enhance Healthcare Efficiencies and Productivity
4. QB3 Adds Zcube As Limited Partner In Mission Bay Capital Fund
5. Team delivers development aid via cell phone animations
6. Top scientists unite to develop global scientific strategy Towards An HIV Cure
7. Family planning programs have success in developing countries, but need to be expanded
8. Cost-effectiveness research needs to be considered in developing new medical technology
9. Delivery Even a Bit Early May Mean Developmental Delays
10. Higher levels of social activity decrease the risk of developing disability in old age
11. Researchers develop outline that may help weigh benefits of new imaging technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... Connecticut Dermatology Group (CDG) is proud and excited ... compassionate dermatologist. Dr. Kim brings an extensive background in cutting-edge dermatology care and ... pleasure to welcome back Dr. Kim to the CDG team” said President and Managing ...
(Date:1/19/2017)... ... January 19, 2017 , ... Sales Focus Inc. (SFI), a Maryland-based ... US market. , Over the past 20 years SFI has been recognized as the ... launched six new clients into the US market. The new clients include: Panacea ...
(Date:1/19/2017)... ... ... Infinity® Massage Chairs announced today that Dan Grover has joined the organization to ... with a total of 15 years experience in consumer goods and an entrepreneurial mindset, ... Direct Sales at Traeger® Wood Pellet Grills. , Grover has elevated each brand ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... the American Osteopathic College of Proctology) announced today the opening of 3 ... California ( http://www.hemorrhoidsremovalcenterscalifornia.com ): Hemorrhoids Center of Los Angeles (Beverly Hills), Hemorrhoids ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... A recent ... opened a global discussion about the benefits of fidgeting to relieve stress and anxiety. ... Jym Daniel. Their Think Ink Pen had just completed a successful Kickstarter campaign ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 18, 2017  Magnetic Insight Inc., leader in ... an agreement with inviCRO LLC to develop intuitive ... system based on inviCRO,s VivoQuant™ visualization and post ... a complete MPI solution package with the Momentum ... cell imaging in vivo. MPI is ...
(Date:1/19/2017)... 2017 The Academy of Managed Care ... (FDA) for its release today of draft guidance ... makers can proactively share clinical and economic information ... emerging therapies awaiting FDA approval. ... AMCP developed during two multi-stakeholder meetings last year ...
(Date:1/18/2017)... , Jan. 18, 2017  Aprima Medical ... records (EHR), practice management (PM) and revenue cycle ... the acquisition of a former reseller Healthcare Data ... of the agreement, Aprima will assume full support ... in 125 medical practices across 15 states. Financial ...
Breaking Medicine Technology: